Ardelyx, Inc. has announced an upcoming poster presentation at the Digestive Disease Week Conference (DDW) on May 2-5, 2026, focusing on patient characteristics associated with treatment patterns for irritable bowel syndrome with constipation (IBS-C). The abstract, authored by a team including Alan Fossa and Kyle Staller, aims to elucidate the impact of these characteristics on gastrointestinal (GI) healthcare resource utilization (HCRU). Additionally, Ardelyx will sponsor a Product Theater session led by Dr. Darren Brenner, which will delve into the pathophysiology of IBS-C and strategies for optimizing patient care.

The significance of this research lies in its potential to inform clinical practices surrounding IBS-C, a condition affecting approximately 12 million people in the U.S. and associated with considerable economic burden and impaired quality of life. The findings from the poster may highlight specific demographic or clinical factors that influence treatment adherence and effectiveness, thereby providing insights that could lead to improved management strategies. Notably, Ardelyx’s IBSRELA® (tenapanor), a locally acting NHE3 inhibitor, has shown promise in reducing both abdominal pain and constipation by enhancing intestinal transit and stool consistency, which could be pivotal in addressing the unmet needs of IBS-C patients.

The takeaway from this development is its potential to shift current research paradigms by emphasizing the importance of personalized treatment approaches in IBS-C management. Understanding patient-specific factors could accelerate the development of tailored therapies and improve patient outcomes, ultimately influencing drug development timelines and healthcare strategies. As the field moves towards more individualized care, findings from Ardelyx’s research may serve as a critical reference point for future studies and clinical applications in the management of IBS-C.

Source: globenewswire.com